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Purpose: Optineurin is a pathogenic gene associated with primary open angle glaucoma (POAG), in which the retinal
ganglion cells (RGCs) are targeted. However, the functions of optineurin, particularly in RGCs, are currently not clear.
We introduced optineurin siRNA into cultured retinal ganglion cell 5 (RGC-5) and PC12 cells to determine the cellular
and molecular mechanisms underlying the role of optineurin in POAG.
Methods: We constructed four optineurin siRNA–expressing plasmids, and transiently transfected them into PC12 cells.
Quantitative real-time PCR, western blot, and fluorescent microscopy were used to determine optineurin expression and
select the most effective optineurin siRNA to construct RGC-5 and PC12 stable transfected cells. Dimethylthiazolyl
diphenyl tetrazolium bromide (MTT) assay and flow cytometry were applied to investigate the role of optineurin siRNA
in  cell  growth  and  apoptosis.  Gene  microarray  and  quantitative  real-time  PCR  were  used  to  screen  and  validate
differentially expressed genes in optineurin siRNA transfected PC12 and RGC-5 cells.
Results: siRNA effectively downregulated optineurin expression in RGC-5 and PC12 stable transfected cells. Optineurin
siRNA significantly inhibited cell growth and increased apoptosis in RGC-5 and PC12 cells. Microarray analysis identified
112 differentially expressed genes in optineurin siRNA transfected RGC-5 cells. Quantitative real-time PCR and western
blot confirmed that the expression of brain-derived neurotrophic factor (Bdnf), neurotrophin-3(Ntf3), synaptosomal-
associated protein 25(Snap25), and neurofilament, light polypeptide(Nefl) was significantly downregulated in RGC-5 and
PC12 cells transfected with optineurin siRNA.
Conclusions: Our study suggested that optineurin downregulation by siRNA in RGCs was an in vitro model for studying
the mechanisms of optineurin effects on POAG. Neuroprotective factor and axonal transport genes may be involved in
the development of POAG and could be novel targets for treating POAG due to optineurin mutation.
Glaucoma is the leading cause of irreversible blindness
worldwide [1-3], and most of the cases are primary open angle
glaucoma (POAG) [1], which is characterized by optic disc
cupping and irreversible loss of retinal ganglion cells [2,3].
However, the pathogenic mechanism of POAG is not clear.
Genetic  changes  play  an  important  role  in  the
pathogenesis  of  glaucoma  [4].  With  the  development  of
molecular  genetics,  in  2002  a  new  gene,  designated  as
optineurin  [5]  (optic  neuropathy  inducing  protein),  was
identified  as  being  associated  with  POAG.  However,  the
gene’s  function  is  unclear.  It  has  been  demonstrated  that
optineurin binds to myosin VI in the Golgi complex and plays
a crucial role in Golgi ribbon formation and exocytosis [6].
There  are  still  arguments  regarding  whether  optineurin
inhibits  or  promotes  apoptosis.  Zhu  et  al.  [7]  found  that
optineurin protects cells by maintaining activation of nuclear
factor-kappaB (NF-κB) activation induced by tumor necrosis
factor  (TNF)-alpha.  However,  optineurin  overexpression
inhibited the protective effects of E3–14.7K on TNF-alpha
receptor 1-induced cell death. Recently, a study revealed that
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optineurin interacted with metabotropic glutamate receptors
(mGluRs)  and  played  an  important  role  in  antagonizing
agonist-stimulated mGluR1a signaling [8]. Weisschuh et al.
[9] used RNA interference to silence optineurin in HeLa cells,
and,  using  microarray  technology,  found  a  series  of
differentially expressed genes.
Although retinal ganglion cells (RGCs) are the target
cells  of  glaucoma,  few  research  regarding  the  impact  of
optineurin on RGCs have been conducted. Therefore, in the
present  study,  we  used  RNA  interference  technology  to
downregulate  the  expression  of  optineurin  in  PC12  and
RGC-5 cells, a pathologic condition mimicking the POAG
caused by optineurin mutation. Dimethylthiazolyl diphenyl
tetrazolium bromide (MTT) assay and flow cytometry were
applied to determine the effects of optineurin on proliferation
and  apoptosis  in  RGC-5  cells.  To  study  the  underlying
mechanisms, we screened differentially expressed genes with
gene  microarray  technology  and  validated  them  with
quantitative real-time PCR and western blot. Our findings will
help us learn the functions of optineurin. They might be also
useful for treating POAG due to optineurin mutation.
METHODS
Cell  culture:  PC12  and  RGC-5  cell  lines  (ATCC)  were
maintained in Dulbecco’s Medium Eagle’s medium (DMEM;
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3314nvitrogen Gibco, Carlsbad, CA) supplemented with 10% fetal
bovine  serum,  100  μg/ml  penicillin,  and  100  μg/ml
streptomycin. Routine testing confirmed that the cells were
free of mycoplasma and viral contaminants during the entire
study period.
Construction of optineurin siRNAs and screening by transient
transfection: We designed four siRNA targeting sequences
according  to  the  rat  optineurin  reference  gene  sequence
(GenBank  NM_145081.3)  by  the  siRNA  Target  Finder
Program (Silencer® Pre-designed siRNA, Ambion, Foster
City, CA). BLAST was performed with the selected siRNA
sequences against expressed sequence tag libraries to ensure
that  only  a  single  gene  (optineurin)  was  targeted.  One
scrambled siRNA (Optineurin–NC) was used as a negative
control. The sequences are described in Table 1. Purified
fragments were digested with BamHI/BglII and inserted into
the pGPU6/GFP/Neo vector (GenPharma, Placentia, CA). All
constructs  were  identified  by  sequencing.  The  resultant
plasmids containing siRNA 1, 2, 3, and 4 and the negative
control  sequences  were  sihoptineurin-1,  sihoptineurin-2,
sihoptineurin-3,  sihoptineurin-4,  and  sihoptineurinNC,
respectively.
Before transfection, cells were seeded into six well plates
at 80% confluency for 12 h. Cell transfection was performed
with  Lipofectamine  2000  (Invitrogen,  Carlsbad,  CA)
according to the manufacturer's instructions: 4.0 µg plasmids
and10 µl Lipofectamine 2000 were used in each well.
To  efficiently  knock  down  optineurin,  cells  were
transfected twice with siRNA on days 1 and 3. Quantitative
real-time PCR was used to select the most effective siRNA
(sihoptineurin-3) from the four candidates, which was used to
establish RGC-5 and PC12 stable transfected cells.
Stable transfection of siRNA: Cells were cultured in six well
plates. Plasmid sihoptineurin-3 and plasmid sihoptineurinNC
were transfected with Lipofectamine 2000 as described above.
Plasmid sihoptineurinNC was used as a negative control. The
cells were screened by G418 for 4 weeks, and several colonies
were obtained. The same concentration of G418 was used to
continue screening for another 4 weeks to obtain a positive
monocolony. Survival colonies were isolated and expanded.
We examined the expression of optineurin in the stable cell
lines  with  fluorescence  microscopy  and  western  blot.  We
successfully established optineurin siRNA stable expression
cell lines in PC12 and RGC-5 cells. We also used electron
microscopy to observe the changes in the stable transfected
cells.
Transmission electron microscopy: Cells were first fixed in
2.5% glutaraldehyde for 1–4 h at 4 °C, and then fixed in 1%
osmium tetroxide for 1 h at room temperature after a 2 h wash
by 0.1 M phosphate buffer. After the cells were briefly washed
with distilled water, routine dehydration was performed. The
plastic embedded mount was prepared as described previously
[10]. Ultrathin sections (100 nm) were cut on a Leica Ultracut
microtome  (Leica  Microsystems,Wetzlar,  Germany),
TABLE 1. OPTINEURIN-NC SEQUENCES.
Gene Sequence (5′-3’)
Optineurin-1 (sihoptineurin 1) GCTGCTGCAGCAAATGAAA
Optineurin-2 (sihoptineurin 2) GGAACTGACTGTGAGCCAAC
Optineurin-3 (sihoptineurin 3) GGGCGATTTGAGGAGCTTTCT
Optineurin-4 (sihoptineuri N4) GCTCCTTCAGGAACACAATAA
Optineurin-NC UAUCGGAACCCUAGGUUCCTT (Forward)
  GGAACCUAGGGUUCCGAUATT (reverse)
TABLE 2. SEQUENCE OF RELATIVE GENES.
Gene Sequence (5′-3′)
GAPDH F: TGATTCTACCCACGGCAAGTT
  R: TGATGGGTTTCCCATTCATGA
Optineurin F: GAAGGAGATGAGGAACAGCG
  R: CAGGAGT TG GCTCACAGTCA
Bdnf F: AGGCACTGGAACTCGCAATG
  R: AAGGGCCCGAACATACGATT
Ntf-3 F: TGCAGAGCATAAGAGTCACC
  R: AAGTCAGTGCTCGGACGTAG
Nefl F: CAGCGTGGGTAGCATAAC
  R: TGATTCACATTGCCGTAGA
Snap-25 F: TTTCCTTCCCTCCCTACC
  R: GGCATCGTTTGTTACCCT
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3315collected on 200 mesh copper grids, stained with uranium and
lead salts, and viewed on a Zeiss 910 transmission electron
microscope (Zeiss Inc., Oberkochen, Germany).
Quantitative real-time reverse transcriptase-PCR analysis:
Total RNA was extracted using TRIzol (Invitrogen) according
to the manufacturer’s instructions Trizol was joined according
to 10 cm2/ml proportion. About 1 µg total RNA from each
sample  was  reverse-transcribed  into  cDNA  with  the
RevertAid™ First Strand cDNA Synthesis Kit.(Fermentans,
Foster City, CA) in a total volume of 20 μl and stored at
−20 °C. Real-time quantitative PCR was used to determine
the  optineurin,  brain-derived  neurotrophic  factor  (Bdnf),
neurotrophin-3  (Ntf3),  synaptosomal-associated  protein  25
(Snap25)  transcripts  using  a  sequence-detection  system
(GeneAmp  5700;  Applied  Biosystems,  Inc.  [ABI],  Foster
City, CA). PCR reactions were performed in a 50 µl reaction
mixture containing 25 µl master PCR mix (SYBR Green PCR
Master  Mix;  ABI),  5  pM  primer  pairs,  and  1  µl  cDNA
samples.  Glyceraldehyde-3-phosphate  dehydrogenase
(GAPDH) was used at the same time as an internal control.
Reactions were performed through the following conditions:
10  min  at  95  °C  for  initial  denaturation,  40  cycles  of
denaturing for 5 s at 95 °C, and annealing for 31 s at 60 °C.
Experiments were repeated 3 times (n=3). All the primers used
in the reactions are described in Table 2.
Protein isolation and western blot analysis: About 100 μl cell
lysis  buffer  (60  mM  of  Tris,  2%  sodium  dodecyl  sulfate
(SDS),  100  mM  of  2-mercaptoethanol,  and  0.01%
bromophenol blue) was added to each of the tissue samples.
An equal amount of protein (10 μg) was loaded onto 10%
sodium  dodecyl  sulfate-polyacrylamide  gels,  and
electrophoresis was performed for 1 h. Following separation
and  transfer  onto  a  polyvinylidene  difluoride  membrane
(Invitrogen), the blots were incubated with 1:500 dilution
optineurin or GAPDH primary antibody (Abcam, Cambridge,
MA)  at  4  °C  overnight.  Horseradish  peroxidase  (HRP)-
conjugated antirabbit IgG secondary antibody was incubated
at room temperature for 2 h at a 1:5,000 dilution. An Enhanced
Chemiluminescence  (ECL)  kit  (Amersham  Bioscience,
Piscataway, NJ) was used to detect blotting signals following
the  manufacturer’s  instructions  Mixed  Reagents  I  and  II
according to 1:1,and then 10 times diluted. The amount of
GAPDH in each sample was measured as an internal control.
Gel-Pro Analyzer software (Media Cybernetics) was used to
analyze the data.
The same western blot analysis protocol was used to
detect Bdnf, Ntf3, Snap25, and Nefh protein expression in
stable transfected RGC-5 cells. All of the antibodies were
purchased from Abcam. Experiments were repeated 3 times
per protein per treatment group (n=3).
3-(4,5)-dimethylthiazol  (-z-y1)-3,5-di-phenyltetrazolium
bromide  assay:  Approximately  200  μl  of  3-(4,5)-
dimethylthiazol  (-z-y1)-3,5-di-  phenyltetrazolium  bromide
(MTT; Sigma-Aldrich, St. Louis, MO) solution (5 mg/ml) was
added into the RGC-5 and PC12 cells at 24 h, 48 h, and 72 h,
respectively, after cell passage to 70% confluence. Cell plates
were then wrapped with aluminum foil and incubated for 4 h
at 37 °C. Cell plates were shaken for 15 min after the MTT
was discarded, the precipitate was solubilized in 100% DMSO
(Sigma)  using  200  μl/well.  Absorbance  of  each  well  was
measured  on  a  microplate  reader  (Wellwash  MK2;
Labsystems Dradon, Helsinki, Finland) at a wavelength of
490 nm. Experiments were repeated 3 times (n=3).
Flow  cytometry:  Cell  apoptosis  was  assessed  with  flow
cytometry  using  an  Annexin  V  FITC/PI  staining  kit
(PharMingen, Becton Dickinson Co., San Diego, CA). After
48 h of transfection, we harvested cells, washed twice in
phosphate buffer solution (PBS; sodium chloride NaCl 40.0
g,  potassium  chloride  KCl  1.0  g,  potassium  dihydrogen
phosphate  anhydrous  KH2PO4  1.0g,  disodium  hydrogen
phosphate anhydrous Na2HPO4 4.6 g, distilled water to make
up to 5 l; 4 °C), resuspended in binding buffer (10 mm HEPES/
NaOH pH 7.4, 140 mm NaCl, 2.5 mM CaCl2), stained with
fluorescein isothiocyanate-conjugated annexin V (Annexin
V-FITC), mixed gently and incubated for 15 min at room
temperature in the dark, and then washed with binding buffer
and analyzed with flow cytometry (FACS Calibar; Becton-
Dickinson)  using  CellQuest  software  (BD,San  Jose,  CA).
Experiments were repeated 3 times (n=3).
Microarray analysis: Agilent dual-channel cDNA microarray
was used for these experiments. Total RNA was isolated from
transfected and untransfected samples by TRIzol as described
previously. Total RNA was further purified using a QIAGEN
RNeasy® Mini Kit (Qiagen, Valencia, CA). A low RNA Input
Linear Amplification Kit (Agilent Technologies, Wilmington,
DE)  was  used  for  cDNA  and  cRNA  synthesis.  aaUTP
(Ambion) was used to create amplified and labeled cRNA
with T7 RNA polymerase, which also amplified the target
material and incorporated Cy3- or Cy5-labeled CTP. cRNA
from the stable transfected samples was amplified with the
incorporation  of  Cy5-CTP,  while  cRNA  from  the  control
samples was labeled using Cy3-CTP and then purified with a
QIAGEN RNeasy® Mini Kit. Cy3 and Cy5 labeled cRNA
samples were maintained in fragmentation buffer at 60 °C for
30 min. Hybridization was completed for each sample with a
whole  separate  Genome  (4×44  K)  microarray  (Agilent
Technologies) at 65 °C in a hybridization oven overnight. We
then washed, stabilized, dried, and immediately scanned the
hybridization slides using the Agilent G2565BA Microarray
Scanner  System  (v  7.0).  A  single  log2  ratio  (SLR)  was
calculated from transfected and normal cells.
RESULTS
Effects of optineurin siRNA on optineurin expression: Four
optineurin  siRNA–expressing  plasmids  (sihoptineurin-1,
sihoptineurin-2,  sihoptineurin-3,  sihoptineurin-4)  and  one
negative  control  (sihoptineurinNC)  were  transiently
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3316transfected into PC12 cells. The inhibition effectiveness of
optineurin of the five siRNAs in PC12 cells was assayed with
quantitative  real-time  PCR.  As  shown  in  Figure  1A,  the
transfected  cells  showed  78.99%,  56.34%,  14.34%,  and
21.22%  expression  relative  to  the  untransfected  cells,
respectively,  of  which  sihoptineurin-2,  −3,  −4  showed  a
significant decrease compared to the control (p<0.01, n=3).
The sihoptineurinNC transfected cells were not significantly
different from the untransfected cells (92.02%, p>0.05, n=3),
indicating  that  the  transfection  procedure  did  not  affect
optineurin expression. Western blot was used to validate the
results  of  quantitative  real-time  PCR  (Figure  1B).
Sihoptineurin-3  was  the  most  effective  siRNA  to  inhibit
optineurin  protein  expression  and  with
83.1%  inhibition  of  expression  versus  untransfected  cells
(p<0.01,  n=3).  Therefore,  we  used  sihoptineurin-3  to
construct  stably  transfected  cell  lines.  Using  western  blot
(Figure 1C) and fluorescence microscopy to identify the cell
lines,  we  constructed  stable  transfected  sihoptineurin-3
RGC-5 and PC12 cell lines, which were used in the following
experiments.
Figure 1. Effects of optineurin siRNA on optineurin expression in transfected cells. A: Quantitative real-time PCR was used to measure
optineurin mRNA expression. Mock transfected cells were set to 100%. Optineurin siRNA no. 3 was the most effective in inhibiting optineurin
mRNA expression and showed 14.34% of expression in Blank cells (p<0.01, n=3). GAPDH served as the endogenous control. B: western
blot  analysis  was  used  to  measure  the  amount  of  optineurin  protein  in  sihoptineurin-1(1),  sihoptineurin-2(2),  sihoptineurin-3(3),
sihoptineurin-4(4), sihoptineurin-NC(5) transient transfected and untransfected PC12 cells. The ratio of inhibition for sihoptineurin-3 was
83.1% (p<0.01, n=3). C: western blot analysis showed the knockdown of optineurin in sihoptineurin-3 stable transfected RGC-5 cells and
stable transfected PC12 cells. Western blot showed that the inhibiting ratio of optineurin was 84.96±0.88% of Blank cells (p<0.01, n=3).
GAPDH served as the loading control. (*p<0.05, **p<0.01, n=3).
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3317Effects of optineurin siRNA on cell growth: As shown in
Figure 2 with the MTT assay, sihoptineurin-3 significantly
inhibited cell growth in stable transfected RGC-5 and PC12
cells  compared  to  controls.  In  the  RGC-5  cells,
sihoptineurin-3 significantly inhibited cell growth at 24 h
(p<0.01, n=3), 48 h (p<0.01, n=3), and 72 h (p<0.001, n=3).
In  the  stable  transfected  PC12  cells,  cell  growth  was
significantly  inhibited  at  48  h  (p<0.01,  n=3)  and  72  h
(p<0.001, n=3). There was no significant difference between
the  negative  control  (NC)  and  untransfected  PC12  cells
(Blank) after 3 days (p>0.05, n=3).
Effects of optineurin siRNA on cell apoptosis: Flow cytometry
was  used  to  identify  cell  apoptosis  in  this  study.  Flow
cytometry showed that cell apoptosis occurred in 30.41%
±2.41%  and  9.91±2.81%  (SD)  in  sihoptineurin-3  stable
transfected  RGC-5  and  PC12  cells,  respectively,  while
11.17%±2.77%  and  8.09%±3.86%  in  RGC-5,  and
4.36±0.87% and 3.55±0.55% in PC12 NC and untransfected
control cells. There was a significant difference between the
experimental groups and the controls (p<0.01 in RGC-5 and
p<0.05 in PC-12, n=3; Figure 3).
Electron  microscopy  showed  nuclear  heterochromatin
margination,  partial  membrane  dissolution,  rough
endoplasmic reticulum expansion, mitochondrial reduction
(Figure 4A), and mitochondrial outer membrane damage, cell
membrane partial dissolution, and apoptotic bodies (Figure
4B) in the sihoptineurin-3 stable transfected RGC-5 cells.
However, in the negative control and untransfected cells, we
observed  nuclear  membrane  integrity,  with  organelles
enriched in cytoplasm (Figure 4C,D). These data indicated
that optineurin is related to cell apoptosis.
Microarray  analysis:  To  investigate  the  molecular
mechanisms underlying optineurin’s effects on cell growth
and apoptosis, gene microarray analysis was applied to scan
the  differentially  expressed  genes  in  RGC-5  cells.  One
hundred twelve genes were identified as being upregulated by
≥1.0 SLR (fold change >2), or downregulated by <-1.0 SLR
(fold change <-2) in RGC-5 stably transfected cells versus
Figure 2. Effects of optineurin siRNA
on  RGC-5  and  PC12  cell  growth  as
measured by the MTT assay. *p<0.01
(versus  sihoptineurin-NC  and  blank),
**p<0.001  (versus  sh-NC  and  blank)
n=3.  In  the  experimental  groups,
sihoptineurin-3  groups  significantly
inhibited  cell  growth  compared  to
controls at 24 h, 48 h, and 72 h.
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3318control. Genes with SLR>2.0 (fold change>4) or SLR<-2.0
(fold change<-4) were selected to do gene function catalog
analysis and were found to be enriched in apoptosis, growth,
and axonal transport (Appendix 1).
Validation  of  differentially  expressed  genes  in  PC12  and
RGCs  cells:  Four  differentially  expressed  genes  with
SLR<-2.0  (fold  change<-4)  were  further  validated.  In  the
PC12  stably  transfected  cells,  quantitative  real-time  PCR
showed  that  Ntf3  was  78.09%  (p<0.05,  n=3),  Bdnf  was
57.52% (p<0.05), Snap25 was 36.40% (p<0.05, n=3), and
Nefl was 55.66% (p<0.05, n=3) of the expression relative to
untransfected cells (Figure 5).
In  the  stable  transfected  RGC-5  cells,  western  blot
analysis demonstrated that the expression of Bdnf was 2.06
fold, Ntf3 was 1.28 fold, Snap25 was 3.119 fold, and Nefl was
2.16 fold lower than that of normal cells (p<0.05, n=3; Figure
6).
DISCUSSION
After optineurin was identified in 1998 [11], Rezaie et al. [5]
found that the incidence of POAG resulting from optineurin
gene mutations was higher than the control group. Recent
studies [12,13] revealed that optineurin genetic mutation and
single  nucleotide  polymorphisms  (SNPs)  were  associated
with open angle glaucoma. However, the mechanisms have
not  been  elucidated.  To  determine  the  comprehensive
molecular mechanisms and signal transduction pathways of
optineurin, Weisschuh et al. [9] used RNA interference to
silence  optineurin  in  HeLa  cells,  and,  using  microarray
technology, found a series of differentially expressed genes.
However, retinal ganglion cells are target cells of glaucoma,
and optineurin is mainly located in the optic nerve [5,14].
Therefore, we chose RGC-5 and PC12 cells as our research
targets and used siRNA to knock down the expression of
optineurin in this study. RGC-5 cells are different from normal
RGCs in electrophysiology and were more appropriate as
Figure 3. Effects of optineurin siRNA on apoptosis of stable transfected RGC-5 cells and PC12 cells as measured with flow cytometry. LR
denotes early apoptosis, and UR is advanced stage apoptosis. (*p<0.05, **p<0.01), n=3. Apoptosis %=Gated (UR+LR)%. Apoptosis rate of
experimental groups is obviously higher than that of sihoptineurin-NC and blank groups.
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3319neuronal retinal precursors [15], but are similar in terms of
molecular  and  genetic  changes  during  apoptosis  and
responses to neuroprotective agents [16-19]. Thus, RGC-5
cells are widely used as a model of RGC. PC12 was also
applied  in  this  study,  because  it  is  widely  used  to  study
neuronal development and function as a tissue culture model.
We  constructed  four  optineurin  siRNA  plasmids  and
transiently transfected them into PC12 cells. Quantitative real-
time PCR and western blot demonstrated that all of the four
siRNAs  significantly  decreased  optineurin  expression  in
PC12  cells.  We  selected  the  most  effective  one,
sihoptineurin-3,  to  establish  RGC-5  and  PC12  stable
transfected cells. The origination of the RGC-5 cell line has
been controversial. RGC-5 cells were found to be of mouse
[15] by sequencing a region of the nuclear Thy1 gene and the
d-loop and tRNA(Phe) gene in mitochondrial DNA. However,
Figure 4. Electron microscopy showed apoptosis in RGC-5 cells after stable transfection of sihoptineurin-3. A: Nuclear heterochromatin
margination,  partial  membrane  dissolution,  rough  endoplasmic  reticulum  expansion,  and  mitochondrial  reduction  were  observed  in
sihoptineurin-3 RGC-5 cells. B: Mitochondrial outer membrane damage, cell membrane partial dissolution, and apoptotic bodies were observed
in sihoptineurin-3 RGC-5 cells. C, D: In sihoptineurin-NC RGC-5 and blank cells, we observed nuclear membrane integrity, with organelles
enriched in cytoplasm.
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3320several other studies [20-22] have found RGC-5 cells to be of
rat origin. We therefore designed the optineurin-3 siRNA
according to the rat optineurin cDNA sequence and found a
significant  effect  of  the  siRNA  on  the  expression  of
optineurin,  as  demonstrated  by  Q-PCR  and  western  blot.
Thus, the significant effect of optineurin-3 siRNA makes the
origin of RGC-5 no longer an issue in this study because it
already  allowed  us  to  investigate  the  consequences  of
inhibiting optineurin expression in the cell line.
In  the  other  experiments,  the  MTT  assay  and  flow
cytometry showed that optineurin knockdown significantly
inhibited cell growth and promoted apoptosis. There have
been  many  controversies  regarding  whether  optineurin
promotes or inhibits cell apoptosis. Word et al. [23] speculated
that optineurin was an important component of the TNF-alpha
signaling  pathway  and  activated  apoptosis.  Kroeber  et  al.
[24] showed that overexpression of wild-type optineurin had
no significant effects on lens epithelial cell apoptosis induced
by TGF-beta1 in mice. Evans and Hollenberg [25] speculated
that overexpression of optineurin might not be a damaging
effect on the trabecular meshwork cells, but a protected gene.
Takahisa Koga [26] found that apoptotic activity increased by
force-expressing  wild-type  optineurin  into  RGC-5  cells.
BumChan Park et al. [21] demonstrated that overexpressed
wild type optineurin resulted in impairment of the Tf uptake
in  RPE  and  RGC-5  cells,  which  could  induce  apoptosis.
Nevertheless, E50K cells induced more dramatic effects than
the wild-type optineurin. Our results suggest that optineurin
mutations may lead to increases in apoptosis and decreases in
cell growth in retinal ganglion cells that may result in POAG.
Differences in these results are due to the different types of
cells  and  different  conditions  of  experiments.  Perhaps,
optineurin  plays  different  roles  in  different  stages  of
apoptosis. Further studies are needed.
To  further  determine  the  molecular  mechanisms
underlying the effects of optineurin on cell apoptosis, we used
microarray technology. We found many signaling pathways
were involved, such as TNF-alpha/nuclear factor-kappaB [7,
27] and Ifn [28], as previously reported. In our study, 112
differentially expressed genes were identified in RGC-5 cells,
of which Bdnf, Nefl, Ntf3 and Snap25 were validated in PC12
cells with quantitative real-time PCR and in RGC-5 with
western  blot  analysis.  These  results  were  not  obtained  in
optineurin knockdown HeLa cells [9] due to the different cell
types and stable transfected cells that we used for microarray
analysis. For the first time, we have revealed that optineurin
may  regulate  cell  growth  and  apoptosis  and  transport  of
neurotransmitters through Bdnf, Ntf3, Nefl, and Snap25.
Snap25 and Nefl usually produce fast and slow transport
of the axon [29,30], and Bdnf and Ntf3 are neuroprotective
factors and could impact cellular proliferation and apoptosis
[31,32]. Bdnf is a neuroprotectant following optic nerve injury
[33] and can support the survival of RGCs in vivo [34-36].
Ntf3, which is a subset of neural crest and placode-derived
neurons, plays a role in increasing survival and leading to
neurite outgrowth. Ntf3 regulates the proliferation of cultured
neural crest progenitor cells grown in a serum-free defined
medium [37]. In addition, Ntf3 also acts as a survival factor
for differentiated neurons in the retina and promotes neuronal
differentiation [38]. Both Bdnf and Ntf3 might play roles in
the development of the rat and chick retina [39,40]. Recent
studies confirmed that Bdnf and Ntf3 could be used to treat
RGC injury [36,41,42], since they could promote the survival
of injured cells. In our research, we found that optineurin
knockdown  significantly  downregulated  Bdnf  and  Ntf3
Figure 5. Validation of microarray data
in  stable  transfected  PC12  cells  with
quantitative real-time PCR. Bdnf was
57.52% of the expression in the Blank
cells,  Ntf3  was  62.42%,  Snap25  was
36.40%, and Nefl was 55.66% (*p<0.05
versus control, n=3).
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3321Figure  6.  Western  blot  analysis
examined  the  changes  in  selected
protein  expression  in  RGC-5  cells.
Protein lysates from RGC-5 cells were
probed with antibodies to Bdnf, Ntf3,
Snap25,  Nefl,  and  GAPDH.  Optical
densitometric analysis was performed to
calculate the relative protein amounts of
siRNA-treated cells compared to Blank
cells. In the sihoptineurin-3 transfected
RGC-5 cells, the expression of Bdnf was
2.06-fold, Ntf3 was 1.28-fold, Snap25
was 3.119-fold, and Nefl was 2.16-fold
lower  than  that  of  Blank  cells,
respectively  (p<0.05;  *p<0.05,
**p<0.01) n=3.
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3322expression  that  was  probably  related  to  the  survival  and
apoptosis of retinal ganglia cells. This indicates that reduced
expression of neuroprotective factors, such as Bdnf and Ntf3,
may be one of the reasons that optineurin mutations lead to
POAG.
Snap25 is located in the presynaptic plasma and plays an
important role in the synaptic vesicle membrane docking and
fusion pathway [43]. Brownlees et al. demonstrated that Nefl
proteins  affect  axonal  transport  of  neurofilaments  and
neurofilament  assembly  in  cultured  mammalian  cells  and
neurons [29]. Snap25 and Nefl are usually implemented as
producers of fast and slow transport [30,44]. In this study, we
found that knockdown of optineurin in RGC-5 downregulated
the expression of Snap25 and Nefl. The result suggested that
optineurin might affect the general rates of slow and fast
axonal transport in vitro and that optineurin is an essential
component for axonal transport. Optineurin might affect the
neurotransmitter  and  neurotrophic  factor  expression  and
transport  in  RGC  apoptosis.  We  speculate  that  optineurin
could be a protective gene for RGC injury, and that optineurin
plays an important role in the axonal transport process.
In the future, further in vitro and in vivo studies are
required  to  show  that  optineurin  causes  glaucoma  via
regulating Bdnf, Ntf3, Snap25, and Nef1.
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List of genes related to apoptosis and growth. To access
the data, click or select the words “Appendix 1.” This will
initiate  the  download  of  a  compressed  (pdf)  archive  that
contains the file.
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